Cyano substituted heteroarylpyrimidinone derivative, preparation method and use thereof

1. A compound as shown in Formula (I):

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof,

wherein

X is selected from —NH—, —O— or —S—;

L 1 is selected from alkylene, cycloalkylene or heterocyclylene;

R 1 is selected from hydrogen atom, alkyl, halogen, alkoxy or cyano, wherein the alkyl or alkoxy is optionally further substituted by one or more substituent groups selected from halogen, hydroxy, cyano, nitro, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 8 R 9 , —C(O)NR 8 R 9 , —C(O)R 6 , —OC(O)R 6 , —S(O) q NR 8 R 9 , —NR 8 S(O) 2 R 9 or —NR 8 C(O)R 9 ;

R 2 is selected from hydrogen atom, hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 8 R 9 , —C(O)NR 8 R 9 , —C(O)R 6 , —OC(O)R 6 , —S(O) q NR 8 R 9 , —NR 8 S(O) 2 R 9 or —NR 8 C(O)R 9 , wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituent groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)R 12 , —C(O)OR 12 or —NR 10 C(O)R 11 ;

R 3 is selected from aryl or heteroaryl, wherein the aryl or heteroaryl is optionally further substituted by one or more substituent groups selected from R 7 ;

R 4 and R 5 are each independently selected from hydrogen atom, alkyl, —OR 6 , —SR 6 , —NR 8 R 9 , —C(O)NR 8 R 9 , —C(O)R 6 , —OC(O)R 6 , —S(O) q NR 8 R 9 , —NR 8 S(O) 2 R 9 or —NR 8 C(O)R 9 ;

or, R 4 and R 5 , together with the atom to which they are attached, form a C 3-8 saturated or partly unsaturated cycloalkyl, or form a C 4-8 saturated or partly unsaturated heterocyclyl having one or more heteroatoms selected from N, O and S(O)q, wherein the cycloalkyl or heterocyclyl is optionally further substituted by one or more substituent groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 8 R 9 , —C(O)NR 8 R 9 , —C(O)R 6 , —OC(O)R 6 , —S(O) q NR 8 R 9 , —NR 8 S(O) 2 R 9 or —NR 8 C(O)R 9 ;

R 7 is each independently selected from hydrogen atom, hydroxy, halogen, cyano, nitro, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 8 R 9 , —C(O)NR 8 R 9 , —C(O)R 6 , —OC(O)R 6 , —S(O) q NR 8 R 9 , —NR 8 S(O) 2 R 9 or —NR 8 C(O)R 9 , wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by a substituent group selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 8 R 9 , —C(O)NR 8 R 9 , —C(O)R 6 , —OC(O)R 6 , —S(O) q NR 8 R 9 , —NR 8 S(O) 2 R 9 or —NR 8 C(O)R 9 ;

R 6 , R 8 and R 9 are each independently selected from hydrogen atom, alkyl, —OR 12 , cyano, hydroxy, halogen, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituent groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)R 12 , —C(O)OR 12 or —NR 10 C(O)R 11 ;

or, R 8 and R 9 , together with the N atom to which they are attached, form a C 4-8 heterocyclyl, wherein the C 4-8 heterocycle comprises one or more atoms selected from N, O and S(O) q , and the C 4-8 heterocycle is optionally further substituted by one or more substituent groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, ═O, —NR 10 R 11 , —C(O)NR 10 R 11 , —C(O)R 12 , —C(O)OR 12 or —NR 10 C(O)R 11 ;

R 10 , R 11 and R 12 are each independently selected from hydrogen atom, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituent groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic ester; and

q is 0, 1 or 2.

2. The compound according to claim 1 , which has a structure of Formula (II):

wherein,

m is 1, 2, 3, 4 or 5; and

L 1 , R 1 , R 2 , R 6 and R 7 are as defined in claim 1 .

3. The compound according to claim 2 , which has a structure of Formula (III):

wherein,

m is 1, 2, 3, 4 or 5.

4. The compound according to claim 2 , which has a structure of Formula (IV):

wherein,

m is 1, 2, 3, 4 or 5.

5. The compound according to claim 1 , wherein R 1 is selected from methyl or trifluoromethyl.

6. The compound according to claim 1 , wherein:

R 2 is selected from tetrazolyl, —C(O)OR 12 or —C(O)NR 8 R 9 ;

R 8 is selected from hydrogen atom or alkyl;

R 9 is selected from cyano or —OR 12 ; and

R 12 is selected from hydrogen atom, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted by one or more substituent groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxylic acid or carboxylic ester.

7. The compound according to claim 1 , wherein L 1 is:

8. The compound according to claim 1 , wherein R 6 is tetrahydropyranyl.

9. The compound according to claim 1 , wherein R 7 is selected from alkoxy or halogen, wherein the alkoxy is optionally further substituted by halogen or cycloalkyl.

10. The compound according to claim 1 , wherein the compound is selected from:

11. A method for preparing the compound of Formula (I) according to claim 1 , comprising:

reacting a compound of Formula (IA) with a compound of Formula (IB) or a salt thereof in the presence of triphenylphosphine and diisopropyl azodicarboxylate, optionally further performing esterolysis, or optionally further reacting with NHR 8 R 9 or a salt thereof, to obtain the compound of Formula (1);

wherein X, L 1 , R 1 -R 5 , R 8 and R 9 are as defined in claim 1 ; and

R 2 is —C(O)OH or —C(O)NR 8 R 9 .

12. A compound as shown in Formula (IA)

or stereoisomers, tautomers or pharmaceutically acceptable salts thereof,

wherein X, L 1 , R 1 and R 2 are as defined in claim 1 .

13. The compound according to claim 12 , which is

14. A method for preparing the compound of Formula (IA) according to claim 12 , comprising:

reacting a compound of Formula (Ia) and a compound of Formula (Ib) in the presence of triphosgene under alkaline conditions, to obtain a compound of Formula (Ic); reacting the compound of Formula (Ic) under alkaline conditions to obtain the compound of Formula (IA);

wherein

R a is selected from alkyl.

15. A pharmaceutical composition, comprising an effective amount of the compound according to claim 1 , and optionally a pharmaceutically acceptable carrier, excipient or a combination thereof.

16. A method for inhibiting ACC in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the compound according to claim 1 or the pharmaceutical composition according to claim 15 .

17. A method for treating ACC-related diseases or conditions, comprising administering the compound according to claim 1 or the pharmaceutical composition according to claim 15 to a subject in need thereof.

18. The method according to claim 17 , wherein the diseases or conditions are metabolic diseases, cancer, fungus, parasitic or bacterial infection; wherein the metabolic diseases are hepatic steatosis, non-alcoholic fatty liver disease, obesity, dyslipidemia, hyperlipidemia, type II diabetes or metabolic syndrome, wherein the obesity is Prader-Willi syndrome, Bardet-Biedl syndrome, Cohen syndrome or MOMO syndrome, wherein the cancer is hepatocellular carcinoma, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, head and neck tumor, melanoma, ovarian cancer or cervical cancer.

19. The compound according to claim 1 , wherein X is —S—.

20. The compound according to claim 9 , wherein R 7 is methoxy, ethoxy, fluoro, difluoromethoxy, fluoroethoxy or cyclopropyl methoxy.

21. The method according to claim 18 , wherein the cancer is hepatocellular carcinoma and non-small cell lung cancer.